Burning Rock Announces Results of 2024 Annual General Meeting
Burning Rock Biotech (NASDAQ: BNR), a company specializing in NGS technology for precision oncology, announced that all resolutions proposed at its 2024 annual general meeting were approved by shareholders. The key resolutions included: the ratification of Ernst & Young Hua Ming LLP as the company's auditor for fiscal year 2024, the re-election of directors Yusheng Han and Gang Lu, and the authorization for directors to implement these resolutions at their discretion.
Burning Rock Biotech (NASDAQ: BNR), un'azienda specializzata nella tecnologia NGS per l'oncologia di precisione, ha annunciato che tutte le delibere proposte durante l'assemblea generale annuale del 2024 sono state approvate dagli azionisti. Le principali delibere includevano: la ratifica di Ernst & Young Hua Ming LLP come revisore dei conti dell'azienda per l'esercizio fiscale 2024, la rielezione dei direttori Yusheng Han e Gang Lu, e l'autorizzazione ai direttori di attuare queste delibere a loro discrezione.
Burning Rock Biotech (NASDAQ: BNR), una empresa especializada en tecnolog铆a NGS para oncolog铆a de precisi贸n, anunci贸 que todas las resoluciones propuestas en su reuni贸n general anual de 2024 fueron aprobadas por los accionistas. Las resoluciones clave incluyeron: la ratificaci贸n de Ernst & Young Hua Ming LLP como auditor de la empresa para el a帽o fiscal 2024, la reelecci贸n de los directores Yusheng Han y Gang Lu, y la autorizaci贸n para que los directores implementen estas resoluciones a su discreci贸n.
Burning Rock Biotech (NASDAQ: BNR)電� 鞝曤皜 膦呾枒頃欖潉 鞙勴暅 NGS 旮办垹鞚� 鞝勲鞙茧 頃橂姅 須岇偓搿�, 2024雲� 鞐半 齑濏殞鞐愳劀 鞝滌晥霅� 氇摖 瓴办潣鞎堨澊 欤检＜霌れ棎 鞚橅暣 鞀轨澑霅橃棃鞚岇潉 氚滍憸頄堨姷雼堧嫟. 欤检殧 瓴办潣鞎堨棎電� 2024 須岅硠鞐半弰 霃欖晥 須岇偓鞚� 臧愳偓鞚胳溂搿� Ernst & Young Hua Ming LLP鞚� 鞀轨澑, 鞚挫偓 Yusheng Han瓿� Gang Lu鞚� 鞛劆鞚� 韽暔霅橃棃鞙茧┌, 鞚挫偓霌れ澊 鞚措煬頃� 瓴办潣鞎堨潉 鞛焿鞐� 霐半澕 鞁滍枆頃� 靾� 鞛堧弰搿� 甓岉暅鞚� 攵�鞐晿電� 雮挫毄鞚� 韽暔霅橃棃鞀惦媹雼�.
Burning Rock Biotech (NASDAQ: BNR), une entreprise sp茅cialis茅e dans la technologie NGS pour l'oncologie de pr茅cision, a annonc茅 que toutes les r茅solutions propos茅es lors de son assembl茅e g茅n茅rale annuelle de 2024 ont 茅t茅 approuv茅es par les actionnaires. Les principales r茅solutions comprenaient : la ratification de Ernst & Young Hua Ming LLP en tant qu'auditeur de l'entreprise pour l'exercice fiscal 2024, la r茅茅lection des administrateurs Yusheng Han et Gang Lu, et l'autorisation pour les administrateurs de mettre en 艙uvre ces r茅solutions 脿 leur discr茅tion.
Burning Rock Biotech (NASDAQ: BNR), ein Unternehmen, das sich auf NGS-Technologie f眉r pr盲zise Onkologie spezialisiert hat, gab bekannt, dass alle bei der Hauptversammlung 2024 vorgeschlagenen Beschl眉sse von den Aktion盲ren genehmigt wurden. Die wichtigsten Beschl眉sse umfassten: die Best盲tigung von Ernst & Young Hua Ming LLP als Wirtschaftspr眉fer des Unternehmens f眉r das Haushaltsjahr 2024, die Wiederwahl der Direktoren Yusheng Han und Gang Lu, sowie die Erm盲chtigung der Direktoren, diese Beschl眉sse nach ihrem Ermessen umzusetzen.
- None.
- None.
GUANGZHOU, China, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the 鈥�Company鈥� or 鈥�Burning Rock鈥�), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that all shareholder resolutions proposed at the Company鈥檚 2024 annual general meeting held today were duly passed. Specifically, the shareholders passed the following resolutions:
- as an ordinary resolution, THAT the appointment of Ernst & Young Hua Ming LLP as auditor of the Company for the fiscal year ending December 31, 2024 be ratified and that the directors of the Company be authorized to determine the remuneration of the auditor;
- as an ordinary resolution, THAT Yusheng Han and Gang Lu be re-elected as directors of the Company; and
- as an ordinary resolution, THAT each of the directors of the Company be authorized to take any and all action that might be necessary to effect the foregoing resolutions as such director, in his or her absolute discretion, thinks fit.
About Burning Rock
Burning Rock Biotech Limited (NASDAQ: BNR), whose mission is to guard life via science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology. Its business consists of i) NGS-based therapy selection testing for late-stage cancer patients, and ii) cancer early detection, which has moved beyond proof-of-concept R&D into the clinical validation stage.
For more information about Burning Rock, please visit: ir.brbiotech.com.
Contact: [email protected]聽
FAQ
What resolutions were passed at Burning Rock's (BNR) 2024 annual general meeting?
Who was appointed as Burning Rock's (BNR) auditor for fiscal year 2024?
Which directors were re-elected to Burning Rock's (BNR) board in 2024?
What type of company is Burning Rock (BNR) and what is their main focus?
